Ascendis Pharma is applying its innovative technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patientsâ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a pipeline of three independent, rare disease endocrinology product candidates in clinical development, and has established oncology as its second therapeutic area of focus. Source
No articles found.
Luna (NASDAQ:LUNA) develops and manufactures new-generation products for the healt...
Luna (NASDAQ:LUNA) develops and manufactures ne...
Health Journal is a leader and influencer in health publishing in Virginia, USA an...
Health Journal is a leader and influencer in he...
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the earl...
Quadrant Biosciences is an epigenetic diagnosti...
At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...
At BioMarin, we focus on developing first-in-cl...
We are ProQR, a company on a mission to create new medicines for patients in need....
We are ProQR, a company on a mission to create ...
Vericel is a leader in advanced therapies for the sports medicine and severe burn ...
Vericel is a leader in advanced therapies for t...
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focu...
Strongbridge Biopharma is a global commercial-s...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing an...
Aeterna Zentaris is a specialty biopharmaceutic...
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
Join the National Investor Network and get the latest information with your interests in mind.